Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis

Table 3 5-Year Risk of Hepatic Decompensation in T2DM Patients with Cirrhosis

	Kaplan Meier Estimates
5-Year Absence of Hepatic Decompensation (%)	After Propensity Score Matching
5-Year Absence of Hepatic Decompensation (%)	Metformin	Metformin + SGLT2-I	P	HR (95%CI)
All	87.62	92.22	0.017	0.63 (0.43–0.93)
Subgroup ^a
Men	87.42	87.78	0.477	0.83 (0.51–1.37)
Women	88.72	96.02	0.086	0.57 (0.29–1.09)
White	87.43	92.51	< 0.01	0.49 (0.31–0.76)
Non-White	93.05	94.31	0.105	0.43 (0.15–1.23)
Hispanic	91.82	98.4	0.230	0.39 (0.08–1.92)
Non-Hispanic	87.84	91.53	0.185	0.73 (0.46–1.16)
Age 39–59	94.86	95.08	0.708	1.18 (0.51–2.7)
Age 60–80	85.84	90.98	< 0.01	0.53 (0.33–0.85)
MASH ^b	95.39	97.43	0.124	0.52 (0.22–1.22)

^a Type 2 diabetes mellitus (T2DM) patients with cirrhosis treated with metformin and sodium glucose cotransporter-2 inhibitors (SGLT2-I) were further divided into demographic subgroups and propensity score matched to the Metformin group by sex, race, ethnicity, and age groups
^b T2DM patients with non-alcoholic steatohepatitis (MASH) Cirrhosis treated with metformin and SGLT2-I were propensity score matched to T2DM patients with MASH cirrhosis on metformin (n = 2,820)
Composite Hepatic Decompensation is defined as having any EMR diagnosis codes for following: ascites, hepatic encephalopathy, and gastric or esophageal variceal bleeding. K-M probabilities values are percent free of death. P values indicate P Log-rank Test
CI, Confidence Interval; HR, Hazard Ratio; K-M, Kaplan Meier

ISSN: 1471-230X